Clinical Trial Update: Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis [Phase 3]

View source ↗

Summary

Phase 3 trial completed evaluating subcutaneous risankizumab for Palmoplantar Pustulosis (PPP) in adult Japanese participants, measuring PPPASI changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Palmoplantar Pustulosis

Drugs mentioned

• Risankizumab (risankizumab)

Snippet

Sponsor: AbbVie | Conditions: Palmoplantar Pustulosis (PPP) | Phase 3 | Status: COMPLETED